title: Pharmacokinetics of darunavir at 900 milligrams and ritonavir at 100 milligrams once daily when coadministered with efavirenz at 600 milligrams once daily in healthy volunteers.
abstract: Ritonavir-boosted darunavir with efavirenz may be considered a nucleoside-sparing regimen for treatment-naïve HIV-infected patients. However, the pharmacokinetics of this combination administered once daily have not been studied. We conducted a three-period interaction study with healthy volunteers. The subjects were given darunavir at 900 mg with ritonavir at 100 mg once daily for 10 days. Efavirenz at 600 mg once daily was added for 14 days. Darunavir-ritonavir was then stopped and efavirenz alone was given for 14 days. At the end of each period, blood was taken predosing and for up to 24 h postdosing to measure the drug concentrations. We recruited seven males and five females ages 24 to 49 years and weighing 50 to 83 kg. The darunavir trough concentrations were reduced after efavirenz administration (geometric mean ratio [GMR], 0.43; 90% confidence interval [CI], 0.32 to 0.57]; P < 0.001). The mean darunavir trough concentrations were 1,180 ng/ml (standard deviation, 1,138 ng/ml) after efavirenz administration, but all darunavir trough concentrations were above the 50% effective concentration (EC(50)) of 55 ng/ml for the wild-type virus. For darunavir, the area under the concentration-time curve from 0 to 24 h (AUC(0-24)) (GMR, 0.86; 90% CI, 0.75 to 0.97; P = 0.05) and the half-life (GMR, 0.56; 90% CI, 0.49 to 0.65; P < 0.001) were also significantly reduced. The darunavir peak concentrations were not significantly changed (GMR, 0.92; 90% CI, 0.82 to 1.03; P = 0.23). The ritonavir trough concentrations (GMR, 0.46; 90% CI, 0.33 to 0.63; P = 0.001), AUC(0-24) (GMR, 0.74; 90% CI, 0.64 to 0.86; P = 0.004), and half-life (GMR, 0.80; 90% CI, 0.75 to 0.86; P < 0.001) were also significantly reduced. The efavirenz half-life was significantly longer when it was coadministered with darunavir-ritonavir than when it was given alone (GMR, 1.66; 90% CI, 1.24 to 2.23; P = 0.01), but there were no differences in the efavirenz trough or peak concentration or AUC(0-24) when it was coadministered with darunavir-ritonavir. Efavirenz reduced the trough concentrations of darunavir significantly, but the concentrations remained above the EC(50) for the wild-type virus. This regimen should be evaluated with treatment-naïve patients with no preexisting resistance.
authors.affiliation: National Healthcare Group, 6 Commonwealth Lane, Singapore 149547, Singapore.
authors.forename: Gaik H
authors.initials: GH
authors.lastname: Soon
authors.forename: Ping
authors.initials: P
authors.lastname: Shen
authors.forename: Eu-Leong
authors.initials: EL
authors.lastname: Yong
authors.forename: Paul
authors.initials: P
authors.lastname: Pham
authors.forename: Charles
authors.initials: C
authors.lastname: Flexner
authors.forename: Lawrence
authors.initials: L
authors.lastname: Lee
mesh_terms: D000328:Adult; D000368:Aged; D000480:Alkynes; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D048588:Benzoxazines / Q000008:administration & dosage / Q000493:pharmacokinetics*; D003521:Cyclopropanes; D000069454:Darunavir; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D019438:Ritonavir / Q000008:administration & dosage / Q000493:pharmacokinetics*; D013449:Sulfonamides / Q000008:administration & dosage / Q000493:pharmacokinetics*
chemical_list: D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D013449:Sulfonamides; C098320:efavirenz; D019438:Ritonavir; D000069454:Darunavir
references.citation: HIV Clin Trials. 2008 Nov-Dec;9(6):418-27
references.pmid: 19203907
references.citation: JAMA. 2008 Aug 6;300(5):555-70
references.pmid: 18677028
references.citation: Antimicrob Agents Chemother. 2009 Jun;53(6):2346-53
references.pmid: 19223624
references.citation: AIDS. 2009 Aug 24;23(13):1679-88
references.pmid: 19487905
references.citation: Clin Infect Dis. 2007 Nov 1;45(9):1230-7
references.pmid: 17918089
references.citation: Antimicrob Agents Chemother. 2008 Nov;52(11):3928-32
references.pmid: 18725446
references.citation: Antimicrob Agents Chemother. 2004 Nov;48(11):4476-8
references.pmid: 15504888
references.citation: J Clin Pharmacol. 2004 Nov;44(11):1273-81
references.pmid: 15496645
references.citation: Antivir Ther. 2010;15(2):275-9
references.pmid: 20386083
references.citation: Antimicrob Agents Chemother. 2003 Jan;47(1):350-9
references.pmid: 12499212
references.citation: AIDS. 2001 Jan 5;15(1):71-5
references.pmid: 11192870
references.citation: N Engl J Med. 2008 May 15;358(20):2095-106
references.pmid: 18480202
references.citation: Drugs. 2009;69(4):477-503
references.pmid: 19323590
references.citation: J Acquir Immune Defic Syndr. 2005 May 1;39(1):63-8
references.pmid: 15851915
references.citation: Antivir Ther. 2007;12(4):509-14
references.pmid: 17668559
references.citation: J Chromatogr B Analyt Technol Biomed Life Sci. 2005 May 25;819(2):259-76
references.pmid: 15833290
references.citation: Rapid Commun Mass Spectrom. 2007;21(15):2505-14
references.pmid: 17610214
references.citation: Ann Intern Med. 2005 Nov 15;143(10):714-21
references.pmid: 16287792
references.citation: J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Nov 15;859(2):234-40
references.pmid: 17964231
references.citation: Antimicrob Agents Chemother. 2005 Jun;49(6):2314-21
references.pmid: 15917527